Valuation: Obalon Therapeutics Inc

Market Cap 13.55M 12.08M 11.26M 10.25M 19.29M 1.3B 19.44M 136M 52.93M 666M 50.85M 49.75M 2.14B P/E 2026 *
-2.97x
P/E 2027 * -2.42x
Enterprise Value 13.55M 12.08M 11.26M 10.25M 19.29M 1.3B 19.44M 136M 52.93M 666M 50.85M 49.75M 2.14B EV / Sales 2026 *
132x
EV / Sales 2027 * 67.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 103K 91.89K 85.61K 77.9K 147K 9.92M 148K 1.03M 402K 5.06M 387K 378K 16.27M 200K 178K 166K 151K 285K 19.26M 287K 2.01M 781K 9.83M 751K 735K 31.6M
Net income -4.49M -4M -3.73M -3.4M -6.39M -432M -6.44M -45.08M -17.54M -221M -16.85M -16.49M -709M -7.85M -7M -6.52M -5.93M -11.18M -756M -11.26M -78.79M -30.66M -386M -29.45M -28.82M -1.24B
Net Debt - -
Logo Obalon Therapeutics Inc
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Employees
-
Sector
-